Her-2/neu receptor

Trastuzumab is a monoclonal antibody directed against the HER-2/neu receptor. HER-2/neu is a member of the erbB (or HER) growth factor receptor family and is expressed at low levels in the epithelial cells of normal breast tissue. The overexpression of HER-2/neu is associated with increased transmission... 

Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ. Monoclonal antibody to HER-2/ neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 1999 59 1347-1355. 

Pietras, R. J., Fendly, B. M., Chazin, V. R., Pegram, M. D., Howell, S. B., and Slamon, D. J. 1994. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9 1829-1838. 

Artemov B, Mori N, Ravi R, Bhuj walla Z. Magnetic resonance molecular imaging of the Her-2/neu receptor. Cancer Res 2003 63 2723-2727. 

HER-2/neu or ERB-B2 Codes for a growth factor receptor Breast, salivary gland, prostate, bladder and ovarian cancers... 

The pathologic evaluation of breast lesions serves to establish the histologic diagnosis and to confirm the presence or absence of other factors believed to influence prognosis. These prognostic factors include the presence of necrosis, lymphatic or vascular invasion, nuclear grade, hormone receptor status, proliferative index, amount of aneuploidy, and HER-2/neu expression. 

Craft, N., Shostak, Y., Carey, N. M., and Sawyers, C. L. 1999. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signalling by the HER-2/neu tyrosine kinase. Nat. Med. 5 280-285. 

Patients with significant visceral involvement of the lung, liver, or brain and those with rapidly progressive disease rarely benefit from hormonal maneuvers, and initial systemic chemotherapy is indicated in such cases. For the 25-30% of breast cancer patients whose tumors express the HER-2/neu cell surface receptor, a humanized monoclonal anti-HER-2/ ew antibody, trastuzumab, is available for therapeutic use alone or in combination chemotherapy. 

Trastuzumab is a recombinant DNA-derived, humanized monoclonal antibody that binds to the extracellular domain of the human epidermal growth factor receptor HER-2/ ew. This antibody blocks the natural ligand from binding and down-regulates the receptor. Trastuzumab is approved for the treatment of metastatic breast cancer in patients whose tumors overexpress HER-2/neu. As a... 

Fig. 3.9 Binding equilibria for different types of antigen. (A) The antigen is a soluble substance, for example TNF-a (B) The antigen is a receptor or enzyme on a cell surface, but is not shed. (C) The antigen is a receptor or enzyme on a cell surface and is shed, for example her-2/neu or CD20.

Emodin has been found to penetrate the active site of the a subunit of CK2, partially overlapping the ATP binding site, thereby preventing binding of the natural substrate.39 It has also been identified as an inhibitor of tyrosine protein kinases, especially the receptor kinase HER-2 neu 40 however, the IC50 value (21 pM) is much higher, suggesting that this may be a secondary effect. 

V8. Visakorpi, T., Kalloniemi, O. P., Koivula, T., Harvey, J., and Isola, J., Expression of epidermal growth factor receptor and erbB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. Mod. Pathol. 5, 643-648 (1992). 

---